Why Amgen’s Pipeline Just Got More Interesting

Amgen Inc. (NASDAQ:AMGN)’s experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease. After 48 weeks, patients with moderate-to-severe disease activity showed statistically significant and clinically meaningful improvements. Most adverse events were mild to moderate, and only a small number of patients stopped treatment. Sjögren’s affects about 1% of the global population and currently has no approved treatment in the U.S.

The result gives Amgen a potential new growth opportunity in autoimmune disease, although it is still several steps away from having a commercial impact. Amgen generated $36.8 billion in revenue in 2025 and invested $7.3 billion in R&D. A successful late-stage asset could strengthen its longer-term pipeline as established products face competition and patent pressures. Amgen expects Prolia sales to decline more rapidly in 2026 following the expiration of U.S. patents and the launch of multiple biosimilars.

Also read: A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too

Amgen Opens a New Chapter in Autoimmune Drug Development

The strongest argument for Amgen Inc. is that dazodalibep has cleared an important clinical hurdle in a disease with significant unmet need. Reuters noted that Sjögren’s affects roughly 1% of the global population, while there are currently no approved treatments for the disease in the U.S. A successful therapy could give Amgen access to a sizable underserved patient population rather than having to compete for market share in an established market.

The result also adds strength to Amgen’s broader autoimmune portfolio. The company already has products such as Otezla, which generated $2.27 billion in sales in 2025. Its earlier investments in inflammation and rare-disease medicines have also expanded its exposure to immune-mediated conditions. Dazodalibep could eventually add another source of growth as Amgen deals with pressure on more mature products.

The safety profile is another positive. Reuters reported that most adverse events were mild to moderate and that few patients discontinued treatment. If those findings hold up in the full dataset, they could support physician adoption and improve the drug’s commercial prospects. Amgen’s shares rose 4% after the trial announcement, showing that investors considered the result meaningful for the company’s pipeline.

New Pipeline Opportunity Still Carries Clinical Risk

The trial result does not yet establish that dazodalibep will become a commercial product. Reuters reported that several details important to investors were not disclosed, and the full data still need to be compared with Novartis’ ianalumab. Amgen Inc. plans to present more detailed results at an upcoming medical meeting, so there is still uncertainty around the size and durability of the benefit.

There is also another major clinical hurdle ahead. Amgen is testing dazodalibep in the separate OASIZ 303 trial, with results expected in the fourth quarter of 2026. William Blair analyst Matt Phipps said two positive late-stage studies would likely be required for FDA approval. That means the latest success alone does not secure a regulatory filing or eventual launch.

Competition could also limit the drug’s opportunity. Novartis and Johnson & Johnson are developing treatments for Sjögren’s, while Amgen’s broader portfolio is already facing patent-related pressure. Prolia generated $4.41 billion in 2025, but Amgen expects sales to decline more rapidly in 2026 as biosimilars enter the market. Dazodalibep therefore needs to move from a promising trial result to a differentiated commercial product to meaningfully offset pressure elsewhere.

Conclusion

Dazodalibep’s late-stage success improves the outlook for Amgen Inc.’s autoimmune pipeline, particularly because it targets a large patient population with no approved treatment in the U.S. The drug could eventually provide a new revenue stream as Amgen faces patent-driven pressure on products such as Prolia.

Still, the investment case depends on the upcoming OASIZ 303 results, the full efficacy and safety data, regulatory requirements, and how dazodalibep compares with competing therapies. For now, the trial removes an important development risk but does not establish the drug’s eventual commercial contribution.

READ NEXT: The AI Security Opportunity Emerging for Palo Alto Networks and Target’s Dividend Has Room to Grow, But Capital Spending Matters

This article is originally published at Insider Monkey.